Golden State Medical Supply – Recall of atenolol and clopidogrel

- On September 29, 2022, Golden State Medical Supply announced a voluntary consumer-level recall of one lot of atenolol 25 mg and one lot of clopidogrel 75 mg tablets because a report was received that a bottle containing clopidogrel was mislabeled as atenolol.
    - Clinical Services will send notifications to members and their prescribers potentially impacted by this recall.
    - The member letters advise members to contact their pharmacy for a replacement.
    - Other clopidogrel and atenolol tablets that are not being recalled are available for patients to use.

- This recall only affects products with the following lot numbers. No other clopidogrel or atenolol products marketed by Golden State Medical Supply are impacted.

Product Description	NDC#	Lot# (Expiration Date)
Atenolol 25 mg tablets	60429-027-10	GS046745 (12/2023)
Clopidogrel 75 mg tablets	51407-032-10	GS046745 (12/2023)

- Patients who suddenly stop taking atenolol, as would happen if clopidogrel were misplaced in the atenolol-labeled bottle, are at increased risk for ischemic (angina, myocardial infarction), hypertensive and arrhythmic adverse events relating to rapid withdrawal of beta antagonism.

- Further, patients who are on atenolol are frequently on concomitant anticoagulant and antiplatelet medications and would be at increased risk for bleeding if clopidogrel were added to the regimen.

- Atenolol tablets are indicated for the treatment of hypertension, long-term management of patients with angina pectoris, and in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction (MI) to reduce cardiovascular mortality.

- Clopidogrel is indicated to reduce the rate of MI and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation MI [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization; and to reduce the rate of MI and stroke in patients with acute STEMI who are managed medically. Clopidogrel is also indicated to reduce the rate of MI and stroke in patients with established peripheral arterial disease or with a history of recent MI or recent stroke.

- To date, Golden State Medical Supply has not received any reports of adverse events related to this recall.

- Patients who have the recalled clopidogrel or atenolol should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled products.

- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.

Continued . . .

- Contact Golden State Medical Supply at **1-800-284-8633** for more information.